Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Asset Utilization Ratio (2021 - 2023)

Candel Therapeutics' Asset Utilization Ratio history spans 3 years, with the latest figure at 0.03 for Q3 2023.

  • For Q3 2023, Asset Utilization Ratio fell 3231.28% year-over-year to 0.03; the TTM value through Sep 2023 reached 0.03, down 3231.28%, while the annual FY2022 figure was 0.0, 4.52% down from the prior year.
  • Asset Utilization Ratio for Q3 2023 was 0.03 at Candel Therapeutics, down from 0.02 in the prior quarter.
  • Across five years, Asset Utilization Ratio topped out at 0.0 in Q3 2021 and bottomed at 0.03 in Q3 2023.
  • The 3-year median for Asset Utilization Ratio is 0.0 (2022), against an average of 0.01.
  • The largest annual shift saw Asset Utilization Ratio soared 42.55% in 2022 before it plummeted 3231.28% in 2023.
  • A 3-year view of Asset Utilization Ratio shows it stood at 0.0 in 2021, then skyrocketed by 42.55% to 0.0 in 2022, then plummeted by 2381.11% to 0.03 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Asset Utilization Ratio are 0.03 (Q3 2023), 0.02 (Q2 2023), and 0.01 (Q1 2023).